Rein Therapeutics (RNTX) Restructuring Costs (2023)

Rein Therapeutics (RNTX) posted quarterly Restructuring Costs of -$12000.0 for Q4 2023, down 300.0% quarter-over-quarter from $6000.0 in Q3 2023.

Rein Therapeutics (RNTX) Restructuring Costs (2023) Analysis & Trends

Rein Therapeutics (RNTX) has reported Restructuring Costs for 1 consecutive years, with -$12000.0 the latest figure, recorded in Q4 2023.

In Q4 2023, Restructuring Costs changed N/A year-over-year to -$12000.0; the TTM figure through Sep 2024 stood at -$12000.0 (changed N/A YoY), while the FY2023 annual figure was $928000.0, changed N/A from the prior year.
Restructuring Costs slipped to -$12000.0 in Q4 2023 per RNTX's latest filing, from $6000.0 in the prior quarter.
Across five years, Restructuring Costs topped out at $1.0 million in Q1 2023 and bottomed at -$88000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.95 Bn	132.10 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn
3	Argenx Se	65.71 Bn	60.52 Bn	1.37 Bn
4	Moderna	60.45 Bn	55.31 Bn	52.00 Mn
5	BeOne Medicines	42.24 Bn	37.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn
7	BioNTech SE	28.64 Bn	10.25 Bn	668.28 Mn
8	Insmed	27.61 Bn	26.45 Bn	358.27 Mn
9	Royalty Pharma	27.26 Bn	26.42 Bn	-
10	Rein Therapeutics	55.39 Mn	55.39 Mn	-

Download Data